An Evelyn D. - 06 Nov 2026 Form 4/A - Amendment Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Reporting relationship: Director
Issuer ticker: MTNB
Reported as of: 06 Nov 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 09 Nov 2026, 16:05:11 UTC
Original report date: 06 Nov 2026
Prior SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jerome D. Jabbour, attorney-in fact for Evelyn D'An

Filing notes and source

Key filing fact

An Evelyn D. filed Form 4/A - Amendment for Matinas BioPharma Holdings, Inc. (MTNB) on 09 Nov 2026.

Key facts

This page summarizes An Evelyn D.'s Form 4/A - Amendment filing for Matinas BioPharma Holdings, Inc. (MTNB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Nov 2026, 16:05.

Change

Previous filing in this sequence was filed on 01 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001325168 Primary reporting owner

D An Evelyn

Relationship: Director
Address: C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER
Signature: /s/ Jerome D. Jabbour, attorney-in fact for Evelyn D'An
Signature date: 09 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTNB transaction Derivative

Stock Option (right to Buy)

Award

Transaction value
Shares: +5,000
Change %
Price: $0.000000^*
Shares after: 5,000
Date: 06 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $1.19
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This amendment on Form 4/A is being filed to amend the Form 4 filed on November 6, 2026, solely to correct an administrative error in the exercise price of the Stock Option previously reported in Column 2 of Table II.

Footnote F2

On November 6, 2026 (the "Grant Date"), the Reporting Person was granted an option to purchase 5,000 shares of the Issuer's common stock, par value $.0001 per share, pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The option will vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) a "Change in Control" (as defined by the Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.